Orgenesis names serial inventor, industry veteran Bala Manian to scientific advisory board

Manian currently serves as a director of Vaccinex, a clinical-stage company pioneering investigational antibody therapies

Boardroom with people
One of his technologies, the first three-color laser, helped filmmakers insert or merge special effects in movies

Orgenesis Inc (NASDAQ:ORGS) has named Bala Manian — a man who holds more than 40 patents and whose Academy Award-winning three-color laser was used in Star Wars — to its scientific advisory board. 

The company said it hopes Manian can help advance its Point-of-Care (POCare) cellular therapy platform.

“Bala Manian will be a very important appointment to the Orgenesis Scientific Advisory Board,” CEO Vered Caplan said in a statement.

“We expect his scientific, medical and entrepreneurial background to make a significant contribution as Orgenesis enters the next phase of its growth. In particular, we look forward to leveraging his technical and medical expertise to help advance our point-of-care cell therapy platform, which we believe has the potential to transform the cell and gene therapy market,” he added.

READ: Orgenesis inks co-development agreement with Accellix to improve quality control in its cellular therapy system

“Having a widely respected visionary and entrepreneur of Bala’s caliber will also assist us in evaluating collaboration and in-licensing opportunities,” Caplan said.

Manian currently serves as a director of Vaccinex Inc (NASDAQ:VCNX), a clinical-stage company pioneering investigational antibody therapies in cancer and Huntington’s disease; is a director of Syngene International Ltd, a public contract research and manufacturing organization; a general partner of Saraswati Partners, a venture capital partnership, and a director at Equillium (NASDAQ:EQ), a clinical-stage biotechnology company developing products to treat severe autoimmune and inflammatory disorders.

Manian has operated as a serial inventor, founding a number of companies that utilize his optical technology in the life sciences sector, such as Lumisys (NASDAQ:LUMI), Digital Optics Corporation, Molecular Dynamics and Biometric Imaging. 

At Biometric Imaging, he served as chief technical officer and led the development of a technology that enables doctors to examine the blood cells of very ill patients and determine the nature and extent of their disease.

Another of his technologies, the first three-color laser, helped filmmakers insert or merge special effects in movies. The laser was used in Star Wars: Return of the Jedi and Indiana Jones: The Last Crusade, and Manian received an Academy Award in 1999 for his work. 

Additionally, he helped develop the first compact barcode laser scanner for supermarkets, while serving as a consultant. Over the years, Manian consulted about on-line quality control at companies including Ford Motor Company (NYSE:F), International Business Machines Corporation (NYSE:IBM), Corning Incorporated (NYSE:GLW), Kodak (NYSE:KODK), and the Union Pacific Corporation (NYSE:UNP).

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

Quick facts: Orgenesis

Price: 5 USD

Market: NASDAQ
Market Cap: $110.47 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...


Orgenesis Inc outlines ways in which the group is aiming to combat the...

Orgenesis Inc (NASDAQ:ORGS) CEO Vered Caplan updates Proactive on ways in which the group is aiming to combat the coronavirus. Caplan spoke to Proactive about its BioShield Program, which is designed to use neutralizing human antibodies as a possible rapid defense and to potentially mitigate the...

1 week, 2 days ago

3 min read